BACKGROUND & AIMS: Esophageal adenocarcinoma (EA) is increasingly common among patients with Barrett’s esophagus (BE). We aimed to provide consensus recommendations based on the medical literature that clinicians could use to manage patients with BE and low-grade dysplasia, high-grade dysplasia (HGD), or early-stage EA. METHODS: We performed an international, multi-disciplinary, systematic, evidence-based review of different management strategies for patients with BE and dysplasia or early-stage EA. We used a Delphi process to develop consensus statements. The results of literature searches were screened using a unique, interactive, web-based data-sifting platform; we used 11,904 papers to inform the choice of statements selected. An a priori threshold of 80% agreement was used to establish consensus for each statement. RESULTS: Eighty-one of the 91 statements achieved consensus despite generally low quality of evidence, including 8 clinical statements: 1. specimens from endoscopic resection are better than biopsies for staging lesions, 2. it is important to carefully map the size of the dysplastic areas, 3. patients that receive ablative or surgical therapy require endoscopic follow-up, 4. high-resolution endoscopy is necessary for accurate diagnosis, 5. endoscopic therapy for HGD is preferred to surveillance, 6. endoscopic therapy for HGD is preferred to surgery, 7. the combination of endoscopic resection and radiofrequency ablation is the most effective therapy, and 8. following endoscopic removal of lesions from patients with HGD, all areas of BE should be ablated. CONCLUSIONS: We developed a data-sifting platform and used the Delphi process to create evidence-based consensus statements for the management of patients with BE and early-stage EA. This approach identified important clinical features of the diseases and areas for future studies.